Trial Profile
A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Epacadostat (Primary) ; Maveropepimut-S (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DeCidE; DeCidE1; DeCidE1
- Sponsors IMV
- 12 Feb 2024 According to a BioVaxys media release, data from this study were presented at the 2023 SGO Annual Meeting on Women's Cancer .
- 01 May 2023 Results (n=22; March 2019 to June 2021) assessing the safety and effectiveness of maveropepimut-S with cyclophosphamide in patients with recurrent ovarian cancer, published in the Clinical Cancer Research.
- 19 Apr 2023 T cell repertoires of pre- and on-treatment (on-Tx) tumor biopsies of patients from this trial to further investigate the fate of T cells elicited by the MVP-S based therapy presented at the 114th Annual Meeting of the American Association for Cancer Research